Advertisement
| applied genetic technologies corporation: Impacts of Applied Genetics United States. Congress. Office of Technology Assessment, 1981 |
| applied genetic technologies corporation: Subcommittee on Healthcare & Technology United States. Congress. House. Committee on Small Business. Subcommittee on Healthcare and Technology, 2011 |
| applied genetic technologies corporation: Genetics and Genomics of Eye Disease Xiaoyi Raymond Gao, 2019-09-12 Genetics and Genomics of Eye Disease: Advancing to Precision Medicine thoroughly examines the latest genomics methods for studying eye disease, including complex eye disorders associated with multiple genes. GWAS, WES, WGS, RNA-sequencing, and transcriptome analysis as employed in ocular genomics are discussed in-depth, as are genomics findings tied to early-onset glaucoma, strabismus, age-related macular degeneration, adult-onset glaucoma, diabetic retinopathy, keratoconus, and leber congenital amaurosis, among other diseases. Research and clinical specialists offer guidance on conducting preventative screenings and counseling patients, as well as the promise of machine learning, computational statistics and artificial intelligence in advancing ocular genomics research. - Offers thorough guidance on conducting genetic and genomic studies of eye disease - Examines the genetic basis of a wide range of complex eye diseases and single-gene and Mendelian disorders - Discusses the application of genetic testing and genetic risk prediction in eye disease diagnosis and patient counseling |
| applied genetic technologies corporation: Cooperative Strategy John Child, David Faulkner, Stephen Tallman, Linda Hsieh, 2019-05-02 Cooperation has become the leading strategy adopted by business and other organizations. It is taking on new forms that are adapted to changing market expectations and technological possibilities in the rapidly evolving business environment. This new edition of Cooperative Strategy provides a comprehensive view of the practical and theoretical literature concerning cooperative strategies, and the alliance and network organizational forms that are the enablers of these strategies. It takes the reader through the stages of developing a cooperative alliance, from choosing a cooperative form and selecting partners, to establishing an alliance and managing the process of cooperation. It examines cooperative strategies in different sectors as well as internationally, and discusses performance criteria and evolution of cooperation over time. With insights from internationally recognized experts on cooperative strategy, this book presents extensive research on the topic while also addressing practical issues of alliance management. |
| applied genetic technologies corporation: SEC Docket United States. Securities and Exchange Commission, 1993 |
| applied genetic technologies corporation: Pediatric Retina Mary E. Hartnett, 2020-10-20 An essential resource for both general ophthalmologists and pediatric and retina specialists, Pediatric Retina, Third Edition, offers a comprehensive overview of all aspects of diagnosis and treatment of major medical and surgical diseases in this challenging field. Dr. Mary Elizabeth Hartnett, along with internationally acclaimed physicians, surgeons, and scientists, guides you through today’s best practices for retinal diseases in infants and children. Hundreds of superb, full-color images (many new to this edition), as well as clinical videos online, provide clear visual support. This is the tablet version which does not include access to the videos mentioned in the text. |
| applied genetic technologies corporation: Federal Register , 1992-08-20 |
| applied genetic technologies corporation: Venture Funding and the NIH SBIR Program National Research Council, Policy and Global Affairs, Committee for Capitalizing on Science, Technology, and Innovation: An Assessment of the Small Business Innovation Research Program, 2009-07-22 The Small Business Administration issued a policy directive in 2002, the effect of which has been to exclude innovative small firms in which venture capital firms have a controlling interest from the SBIR program. This book seeks to illuminate the consequences of the SBA ruling excluding majority-owned venture capital firms from participation in SBIR projects. This book is part of the National Research Council's study to evaluate the SBIR program's quality of research and value to the missions of five government agencies. The other books in the series include: An Assessment of the SBIR Program (2008) An Assessment of the SBIR Program at the National Science Foundation (2007) An Assessment of the Small Business Innovation Research Program at the National Institutes of Health (2009) An Assessment of Small Business Innovation Research Program at the Department of Energy (2008) An Assessment of the Small Business Innovation Research Program at the National Aeronautics and Space Administration (2009) An Assessment of the Small Business Innovation Research Program at the Department of Defense (2009) |
| applied genetic technologies corporation: Inflammatory immune disease: Molecular mechanisms, translational approaches and therapeutics volume II Tao Xu, Qingzhong Xiao, Jian Gao, Cheng Chen, 2023-03-17 |
| applied genetic technologies corporation: Impacts of Applied Genetics , 1981 |
| applied genetic technologies corporation: The Potential Environmental Consequences of Genetic Engineering United States. Congress. Senate. Committee on Environment and Public Works. Subcommittee on Toxic Substances and Environmental Oversight, 1984 |
| applied genetic technologies corporation: Directory of Companies Required to File Annual Reports with the Securities and Exchange Commission Under the Securites Exchange Act of 1934, Alphabetically and by Industry Groups , 1989 |
| applied genetic technologies corporation: Abstracts of Small Business Innovation Research (SBIR) Phase I and Phase II Projects United States. Department of Health and Human Services. Small Business Innovation Research Program, 1985 |
| applied genetic technologies corporation: Precision Medicine in Practice: Molecular Diagnosis Enabling Precision Therapies, An Issue of the Clinics in Laboratory Medicine Ryan J. Schmidt, 2020-06-21 This issue of Clinics in Laboratory Medicine will cover Precision Medicine in Practice: Molecular Diagnosis Enabling Precision Therapies. Curated by Dr. Ryan J. Schmidt, this issue is one of four selected each year by the series Consulting Editor, Milenko Tanasijevic. The volume will include articles on: Features of a Comprehensive Precision Medicine Program for Constitutional Genetic Disorders, Establishing a Precision Medicine Center of Excellence for Rare Disease, High-throughput DNA Sequencing for Rare Disease Diagnosis, Enhancing Diagnosis through RNA Sequencing, Interpretation of Rare Genetic Variants, Clinical Bioinformatics, Precision Therapies for Retinal Dystrophy, Precision Therapies for Muscular Dystrophy, Therapeutic Gene Editing, High Throughput Functional Studies of Genetic Variants, and Patient-specific Disease Models. |
| applied genetic technologies corporation: Pharmacologic Therapy of Ocular Disease Scott M. Whitcup, Dimitri T. Azar, 2017-06-05 There have been major advancements in the pharmacologic treatment of eye diseases over the past decade. With newly discovered disease targets and novel approaches to deliver therapeutic compounds to the eye, patients are seeing improved outcomes. Not only are there better treatments for diseases where treatments existed, we now have effective therapy for previously untreatable and blinding eye disorders. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve. The first section of the volume reviews general principles of ocular pharmacology, pharmacokinetics, pharmaceutical sciences, and drug delivery. In addition, the volume provides an up to date guide to the pharmacologic approach to the key eye diseases that threaten sight or ocular function. |
| applied genetic technologies corporation: Impacts of applied genetics : micro-organisms, plants, and animals. , |
| applied genetic technologies corporation: Plunkett's Biotech & Genetics Industry Almanac 2006: The Only Complete Reference to the Business of Biotechnology and Genetic Engineering Plunkett Research, Ltd, 2005 A complete guide to the business of biotech, genetics, proteomics and related services. Complete profiles of nearly 450 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology. |
| applied genetic technologies corporation: Commercial Biotechnology , 1984 |
| applied genetic technologies corporation: Advances in Ophthalmology and Optometry 2017 Myron Yanoff, Madhura A. Tamhankar, An Vo, Allan E. Wulc, Jesse L. Berry, Alan S. Crandall, Paul B. Freeman, Ronni M. Lieberman, Joseph M. Ortiz, Leonard J. Press, Aparna Ramasubramanian, Narsing Rao, 2017-08-01 Advances in Ophthalmology and Optometry reviews the most current practices in both ophthalmology and optometry. A distinguished editorial board, headed by Dr. Myron Yanoff, identifies key areas of major progress and controversy and invites expert ophthalmologists and optometrists to contribute original articles devoted to these topics. Topics covered this volume include, but are not limited to, technology in the evolution of eye care, myopia, anti-VEGF medications in retinopathy of prematurity, current management of retinoblastoma, secondary angle-closure glaucoma, management of conjunctival bleb leaks, newer therapies for giant cell arteritis, nystagmus, corneal crosslinking, corneal inlays for treatment of presbyopia, orbital floor management, refinements in the conjunctivomullerectomy procedure, emerging intraocular infections of global significance, and recent advances in ocular imaging, among others. |
| applied genetic technologies corporation: Design of Nanostructures for Versatile Therapeutic Applications Alexandru Mihai Grumezescu, 2018-02-03 Design of Nanostructures for Versatile Therapeutic Applications focuses on antimicrobial, antioxidant and nutraceutical applications of nanostructured materials. Many books discuss these subjects, but not from a pharmaceutical point-of-view. This book covers novel approaches related to the modulation of microbial biofilms, antimicrobial therapy and encapsulate polyphenols as antioxidants. Written by an internationally diverse group of academics, this book is an important reference resource for researchers, both in biomaterials science and the pharmaceutical industry. - Assesses the most recently developed nanostructures that have potential antimicrobial properties, explaining their novel mechanical aspects - Shows how nanoantibiotics can be used to more effectively treat disease - Provides a cogent summary of recent developments in nanoantimicrobial discovery, allowing readers to quickly familiarize themselves with the topic |
| applied genetic technologies corporation: Clinical Trials in Retinitis Pigmentosa Treatment Jeffrey N. Weiss, |
| applied genetic technologies corporation: The Forever Fix Ricki Lewis, 2012-03-13 Lewis pens the first book to tell the fascinating story of gene therapy: how it works, the science behind it, how patients (mostly children) have been helped and harmed, and how scientists learned from each trial to get one step closer to the promise of a cure. |
| applied genetic technologies corporation: Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases Christopher L. Cioffi, 2020-09-23 This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerging gene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy. |
| applied genetic technologies corporation: Handbook of Clinical Nanomedicine Raj Bawa, Gerald F. Audette, Brian Reese, 2016-04-27 This unique handbook (60 chapters) examines the entire product life cycle, from the creation of nanomedical products to their final market introduction. While focusing on critical issues relevant to nanoproduct development and translational activities, it tackles topics such as regulatory science, patent law, FDA law, ethics, personalized medicin |
| applied genetic technologies corporation: Directory of Companies Required to File Annual Reports with the Securities and Exchange Commission Under the Securities Exchange Act of 1934, Alphabetically and by Industry Groups , 1990 |
| applied genetic technologies corporation: The importance of the biotechnology industry and venture capital support in innovation United States. Congress. House. Committee on Small Business. Subcommittee on Rural Enterprises, Agriculture, and Technology, 2005 |
| applied genetic technologies corporation: Directory of Companies Required to File Annual Reports with the Securities and Exchange Commission Under the Securities Exchange Act of 1934, Alphabetically and by Industry Groups United States. Securities and Exchange Commission. Office of Reports and Information Services, 1976* |
| applied genetic technologies corporation: Next Therapeutic Targets in Ocular Diseases Ryoji Yanai, Yoko Okunuki, Dong Ho Park, Embong Zunaina, 2022-07-18 |
| applied genetic technologies corporation: The Next Wave Susan Coleman, Alicia M. Robb, 2016-09-07 You may be familiar with the success stories of Spanx, GoldieBlox, and other women-owned businesses that have taken their markets by storm. But, today, only two percent of women-owned firms generate more than one million dollars annually. The Next Wave is here to help women drive up that number. Drawing on the Kauffman Firm Survey and many other sources, Susan Coleman and Alicia M. Robb cull together data-driven advice for women-owned, growth-oriented businesses as they finance their expansion. They not only consider the unique approaches and specific concerns of female business owners, but also take into account the growing pool of investors who will play a role in selecting and grooming a new generation of women entrepreneurs. Since growth-oriented firms typically require external capital, the investor perspective is critical. Telling entrepreneurs what the research means for them, outfitting them with resources, and illustrating the road ahead with real world cases, this book serves as a pioneering strategy guide for the next wave of women who want to go big to bring home their goals. |
| applied genetic technologies corporation: Reverse Acronyms, Initialisms, & Abbreviations Dictionary , 2009 |
| applied genetic technologies corporation: Disposable Bioprocessing Systems Sarfaraz K. Niazi, 2016-04-19 Written by a researcher with experience designing, establishing, and validating biological manufacturing facilities worldwide, this is the first comprehensive introduction to disposable systems for biological drug manufacturing. It reviews the current state of the industry; tackles questions about safety, costs, regulations, and waste disposal; and guides readers to choose disposable components that meet their needs. This practical manual covers disposable containers, mixing systems, bioreactors, connectors and transfers, controls and sensors, downstream processing systems, filling and finishing systems, and filters. The author also shares his predictions for the future, calling disposable bioprocessing technology a game changer. |
| applied genetic technologies corporation: Plunkett's Biotech & Genetics Industry Almanac 2007: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies Plunkett Research Ltd, Jack W. Plunkett, 2006-09 Presents a market research guide to the business of biotech, genetics, proteomics and related services - a tool for strategic planning, competitive intelligence, employment searches, or financial research. This title provides profiles of over 400 biotech companies and in-depth chapters on trends. |
| applied genetic technologies corporation: Applied Ethics at the Turn of the Millenium International Association for Philosophy of Law and Social Philosophy. World Congress, 2001 Burton M. Leiser: Preface Elspeth Attwooll / Annette Brockmoller: Preface Rafael Encinas de Munagorri: Les Problemes de preuve poses par l'evolution des sciences et des technologies Richard A. L. Gambitta / Gary S. Kitchen: Genetic Engineering and the Law Mariachiara Tallacchini: The Patentability of Human Biological Materials Joan C. Callahan: Liberalism, Reproductive Technologies, and Feminist Skepticism Gerry Maher: Future Trends in Computer-Generated Pornography: Ethical Principle and Legal Regulation of Bespoke Pornography Fernando Galindo: La puesta en practica de la regulacion de Internet por la Filosofia del Derecho comunicativa Richard T. De George: Business Ethics and The International Legal Coordination Problem Takao Katsuragi: On Multi-Value Structure or Market Ethics Francois Ost / Mark van Hoecke: From contract to transmission Robert Isaak: Philosophical Bases of Green Logic |
| applied genetic technologies corporation: Nanomedicine Michael Hehenberger, 2015-06-18 By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients, and for close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of |
| applied genetic technologies corporation: Fluorescence Lifetime Imaging Ophthalmoscopy Martin Zinkernagel, Chantal Dysli, 2019-07-29 This book focuses on the emerging non-invasive imaging technique of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO). FLIO reveals unique information on retinal diseases, ranging from age-related macular degeneration and vascular diseases to hereditary retinal dystrophies. Fluorescence lifetimes enable the evaluation of disease progression before irreversible structural changes occur. The image acquisition is suitable for diagnostic purposes and follow-up examinations to investigate the natural course of disease, and to monitor the effects of possible therapies. This book fills the gap between available literature and gives state-of-the-art guidance on the principles of the FLIO technique, image acquisition, and data analysis. Written by a team of expert leaders within this field, this book will be relevant for scientists and clinicians with an interest in ophthalmoscopy. |
| applied genetic technologies corporation: Two Watershed Projects of the Soil Conservation Service United States. Congress. Senate. Committee on Environment and Public Works. Subcommittee on Water Resources, 1984 |
| applied genetic technologies corporation: SEC Docket United States. Securities and Exchange Commission, 1994-03 |
| applied genetic technologies corporation: Retinal Degenerative Diseases John D. Ash, Christian Grimm, Joe G. Hollyfield, Robert E. Anderson, Matthew M. LaVail, Catherine Bowes Rickman, 2014-03-24 This book will contain the proceedings of the XV International Symposium on Retinal Degeneration (RD2012). A majority of those who will speak and present posters at the meeting will contribute to this volume. The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at understanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the “best” and “most important” meetings in the field. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2010. These include the role of inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2010 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected in the volume. |
| applied genetic technologies corporation: Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies Jack W. Plunkett, 2007-09 A market research guide to the business of biotech, genetics, proteomics and related services. It offers tools for strategic planning, competitive intelligence, employment searches, or financial research. It features profiles of nearly 400 leading biotech companies and includes chapters on trends. |
| applied genetic technologies corporation: State-by-state Biotechnology Directory , 1996 Provides contact information for individual companies, state contacts, biotechnology centers and key regulatory individuals--Introd. |
APPLIED GENETIC TECHNOLOGIES CORPORATION
• the underlying genetic defect is well characterized; • the underlying genetic defect can be addressed by approaches amenable with the use of AAV, such as gene replacement, RNA …
Applied Genetic Technologies Corporation 2017 ANNUAL …
efforts to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. 2017 was a landmark year in the field of ocular gene therapy, highlighted …
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a …
rAAV2tYF-CB-hRS1 is a replication-incompetent, recombinant adeno-associated virus (rAAV) vector that expresses the retinoschisin (RS1) protein after the vector enters retinal cells. This …
UNITED STATES SECURITIES AND EXCHANGE COMMISSION …
Applied Genetic Technologies Corporation 14193 NW 119th Terrace, Suite 10 Alachua, FL 32615 Re: Applied Genetic Technologies Corporation Registration Statement on Form S-3 Filed April …
APPLIED GENETIC TECHNOLOGIES CORPORATION
Applied Genetic Technologies Corporation (“AGTC”) is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to Table of Contents • the underlying genetic …
Applied Genetic Technologies Corporation - Cash …
Dec 1, 2022 · Existing American-style Applied Genetic Technologies Corporation options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue …
( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) …
genetically altered by recombinant genetic engineering for improved rAAV production . provide the cells , upon infection , with all of the components necessary to produce rAAV . The method …
Applied Genetic Technologies Corporation - Extended Tender …
Nov 29, 2022 · Applied Genetic Technologies Corporation (AGTC) is the subject of an Extended Offer to Purchase (The “Offer”), as described below: Purchaser: Alliance Acquisition Sub, Inc., …
Applied Genetic Technologies Corporation (2024)
comprehensive documents on emerging genetic technologies and their implications for society The authors discuss the opportunities and problems involved describe current techniques and …
Applied Genetic Technologies Corporation - stifel.com
Applied Genetic Technologies Corporation We are offering (i) 16,741,573 shares of our common stock, par value $0.001 per share and (ii) accompanying warrants, which we refer to herein as …
Applied Genetic Technologies Corporation - stifel.com
“we,” “us” and “our” in this prospectus to refer to Applied Genetic Technologies Corporation. Overview We are a clinical-stage biotechnology company using our proprietary gene therapy …
Keystone Property Group’s Mixed-Use ... - Keystone …
Applied Genetic Technologies Corporation (AGTC) will also move to The Curtis, where the clinical stage biotechnology company that uses a proprietary gene therapy platform to develop …
Applied Genetic Technologies Corporation Fundamental …
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with …
AppliedGeneticTechnologiesCorporation 2015 ANNUAL REPORT
As used herein, except as otherwise indicated by context, references to “we,” “us,” “our,” or the “Company” refer to Applied Genetic Technologies Corporation. PART I ITEM 1. BUSINESS …
OFFICE OF CLIMATE,LICENSING & RESOURCE USE - EPA
TMC Pharma Services, UK representing Applied Genetic Technologies Corporation of Alachua, Florida, USA notified the Environmental Protection Agency (Agency) on 30th April 2010 of …
APPLIED GENETIC TECHNOLOGIES CORPORATION
APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 59-3553710 (State or Other Jurisdiction of Incorporation or …
AppliedGeneticTechnologiesCorporation 2014 ANNUAL REPORT
“Company” refer to Applied Genetic Technologies Corporation. PART I ITEM 1. BUSINESS Overview We are a clinical-stage biotechnology company developing gene therapy products …
APPLIED GENETIC TECHNOLOGIES CORPORATION
APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 59-3553710 (State or Other Jurisdiction of Incorporation or …
APPLIED GENETIC TECHNOLOGIES CORPORATION
Oct 28, 2020 · Welcome to the 2021 Annual Meeting of Stockholders of Applied Genetic Technologies Corporation (the “Company”). We wish to conduct an informative and …
APPLIED GENETIC TECHNOLOGIES CORPORATION
APPLIED GENETIC TECHNOLOGIES CORPORATION 14193 NW 119th Terrace, Suite 10 Alachua, Florida 32615 NOTICE OF 2022 ANNUAL MEETING OF STOCKHOLDERS Dear …
Applied Genetic Technologies Corporation - Wikipedia
Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including …
AGTC Announces Expansion of Manufacturing and Analy…
May 13, 2021 · AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic …
Applied Genetic Technologies Corp - AnnualReports.com
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited …
AGTC Announces Expansion of Manufacturing and Analytics …
May 13, 2021 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: …
Applied Genetic Technologies Corporation Company Profil…
Company Description: Applied Genetic Technologies Corporation (AGTC) has its eye fixed on developing gene therapies for acquired and inherited …
